Related references
Note: Only part of the references are listed.Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Molecular profiling for precision cancer therapies
Eoghan R. Malone et al.
GENOME MEDICINE (2020)
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)
Keith T. Flaherty et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis
Antoine Italiano et al.
CANCERS (2020)
New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology
Perrine Janiaud et al.
CANCER TREATMENT REVIEWS (2019)
New clinical trial designs in the era of precision medicine
Elena Garralda et al.
MOLECULAR ONCOLOGY (2019)
Genomic characterization of metastatic breast cancers
Francois Bertucci et al.
NATURE (2019)
Molecular Profiling of Pancreatic Cancer Patients-Response
Michael J. Pishvaian et al.
CLINICAL CANCER RESEARCH (2018)
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
Christophe Massard et al.
CANCER DISCOVERY (2017)
Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer
Mariaelena Pierobon et al.
CLINICAL CANCER RESEARCH (2017)
A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2-negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol
Iben Kuemler et al.
BMC CANCER (2015)
Topoisomerase-1 gene copy aberrations are frequent in patients with breast cancer
Iben Kumler et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Precision medicine for metastatic breast cancer-limitations and solutions
Monica Arnedos et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer
Gayle S. Jameson et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses
Apostolia-Maria Tsimberidou et al.
CLINICAL CANCER RESEARCH (2014)
A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer
Iben Kumler et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development
Jan Stenvang et al.
FRONTIERS IN ONCOLOGY (2013)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Progression-Free Survival Ratio As End Point for Phase II Trials in Advanced Solid Tumors
Marc Buyse et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers
Daniel D. Von Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy
Ioannis Kostopoulos et al.
BMC CANCER (2009)
Predictive biomarkers of chemotherapy efficacy in colorectal cancer: Results from the UK MRC FOCUS trial
Michael S. Braun et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both
EA Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
